{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:19:25Z","timestamp":1792318765287,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cpcardiol.2022.101478","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T12:21:15Z","timestamp":1667478075000},"page":"101478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Electrocardiographic Features of Immune Checkpoint Inhibitor-Associated Myocarditis"],"prefix":"10.1016","volume":"48","author":[{"given":"Wenhua","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bazoukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Baranchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-1253","authenticated-orcid":false,"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101478_bib0001","article-title":"Recurrent myocarditis induced by immune-checkpoint inhibitor treatment is accompanied by persistent inflammatory markers despite immunosuppressive treatment","volume":"5","author":"Aghel","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0002","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0003","first-page":"e8093","article-title":"A case of acute heart failure following immunotherapy for metastatic lung cancer","volume":"12","author":"Al-Obaidi","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0004","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/eurheartj\/ehab219","article-title":"Slow bidirectional ventricular tachycardia as a manifestation of immune checkpoint inhibitor myocarditis","volume":"42","author":"Alhumaid","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0005","first-page":"21","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series","volume":"6","author":"Arora","year":"2020","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy","volume":"47","author":"Balanescu","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0007","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0009","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.21037\/apm-20-2449","article-title":"Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature","volume":"10","author":"Bi","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0011","first-page":"e4869","article-title":"Nivolumab-induced third degree atrioventricular block in a Patient with Stage IV Squamous Cell Lung Carcinoma","volume":"11","author":"Bukamur","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0012","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.21037\/tcr-21-470","article-title":"Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report","volume":"10","author":"Cao","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0014","article-title":"Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study","volume":"48","author":"Chan","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.18.00208","article-title":"Myocarditis with radiotherapy and immunotherapy in multiple myeloma","volume":"14","author":"Chang","year":"2018","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.cpcardiol.2022.101478_bib0016","article-title":"Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation","volume":"8","author":"Charles","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0017","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.727445","article-title":"Case report: cardiac toxicity associated with immune checkpoint inhibitors","volume":"8","author":"Chen","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0019","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaccas.2019.12.045","article-title":"A fatal case of pembrolizumab-induced myocarditis in non-small cell lung cancer","volume":"2","author":"Cohen","year":"2020","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0021","first-page":"e27112","article-title":"Pembrolizumab-induced myocarditis and delayed acute inflammatory demyelinating polyradiculoneuropathy","volume":"14","author":"Dalal","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0022","first-page":"e26034","article-title":"Pembrolizumab-induced myocarditis and pancreatitis in a patient with colon cancer: a case report","volume":"14","author":"Delgado-Lazo","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0023","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13256-022-03487-4","article-title":"Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report","volume":"16","author":"Delombaerde","year":"2022","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0024","first-page":"203","article-title":"ICIs-related cardiotoxicity in different types of cancer","volume":"9","author":"Dong","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hemonc.2020.04.006","article-title":"Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"15","author":"Fuentes-Antras","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0026","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0027","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.hrcr.2020.07.015","article-title":"Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0029","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMcpc1900423","article-title":"Case 30-2019: a 65-year-old woman with lung cancer and chest pain","volume":"381","author":"Guiney","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0030","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1097\/MJT.0000000000000968","article-title":"Atezolizumab induced myocarditis on a background of cardiac amyloidosis","volume":"26","author":"Gupta","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0031","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799077","article-title":"Case Report: glucocorticoid effect observation in a ureteral urothelial cancer patient with ici-associated myocarditis and multiple organ injuries","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0033","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cllc.2019.10.008","article-title":"Fatal simultaneous multi-organ failure following pembrolizumab treatment for refractory thymoma","volume":"21","author":"Hyun","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223252","article-title":"New drugs and new toxicities: pembrolizumab-induced myocarditis","author":"Inayat","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0035","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s12328-021-01442-2","article-title":"A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma","volume":"14","author":"Iwasaki","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0036","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"47","author":"Jain","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0037","doi-asserted-by":"crossref","first-page":"ytab342","DOI":"10.1093\/ehjcr\/ytab342","article-title":"A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil","volume":"5","author":"Jespersen","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.995121","article-title":"Sintilimab induced ICIAM in the treatment of advanced HCC: a case report and analysis of research progress","volume":"13","author":"Ji","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0039","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0040","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4022\/jafib.2461","article-title":"Incidence of cancer treatment induced arrhythmia associated with immune checkpoint inhibitors","volume":"13","author":"Joseph","year":"2021","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0041","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring","volume":"57","author":"Katsume","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0042","article-title":"Pembrolizumab-induced mobitz type 2 second-degree atrioventricular block","volume":"2020","author":"Khan","year":"2020","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0045","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1177\/1078155220904152","article-title":"Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge","volume":"26","author":"Lee","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0046","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1016\/j.transproceed.2018.08.044","article-title":"Acute cellular rejection and infection rates in alemtuzumab vs traditional induction therapy agents for lung and heart transplantation: a systematic review and meta-analysis","volume":"50","author":"Li","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0047","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ehf2.13912","article-title":"Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration","volume":"9","author":"Liu","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0048","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaccas.2022.04.020","article-title":"Checkpoint immunotherapy-induced myocarditis and encephalitis complicated with complete AV block: not all hope is lost","volume":"4","author":"Lorente-Ros","year":"2022","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0049","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report","volume":"25","author":"Mahmood","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0050","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0051","doi-asserted-by":"crossref","first-page":"e13831","DOI":"10.1111\/eci.13831","article-title":"Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis","author":"Malaty","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0052","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.2147\/CMAR.S185202","article-title":"Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges","volume":"11","author":"Martin Huertas","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0053","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1536\/ihj.20-162","article-title":"A fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma","volume":"61","author":"Matsui","year":"2020","journal-title":"Int Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0054","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2169\/internalmedicine.2596-18","article-title":"Nivolumab-induced myocarditis successfully treated with corticosteroid therapy: a case report and review of the literature","volume":"58","author":"Matsuo","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.acr.2022.03.006","article-title":"Cardiac complications of cancer therapies","volume":"155","author":"Mauro","year":"2022","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0056","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.hrcr.2019.06.006","article-title":"Immune checkpoint inhibitor-mediated myocarditis and ventricular tachycardia storm","volume":"5","author":"McDowall","year":"2019","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0057","first-page":"1059","article-title":"Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0058","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13256-021-03097-6","article-title":"Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report","volume":"15","author":"Miyauchi","year":"2021","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0059","first-page":"391","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0060","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2169\/internalmedicine.9161-21","article-title":"An autopsy case of late-onset fulminant myocarditis induced by nivolumab in gastric cancer","volume":"61","author":"Naganuma","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0061","doi-asserted-by":"crossref","first-page":"e004699","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0062","doi-asserted-by":"crossref","first-page":"e01177","DOI":"10.1213\/XAA.0000000000001177","article-title":"Unanticipated myocarditis in a surgical patient treated with pembrolizumab: a case report","volume":"14","author":"Nierstedt","year":"2020","journal-title":"A A Pract"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0063","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2169\/internalmedicine.8575-21","article-title":"Sinus node dysfunction co-occurring with immune checkpoint inhibitor-associated myocarditis","volume":"61","author":"Nishikawa","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0064","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cjco.2022.03.007","article-title":"A case of lung cancer with very-late-onset immune checkpoint inhibitor-related myocarditis","volume":"4","author":"Nishikawa","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12471-021-01655-7","article-title":"Immune checkpoint inhibitor-associated myocarditis: case reports and a review of the literature","volume":"30","author":"Osinga","year":"2022","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0066","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.21037\/cdt-21-147","article-title":"Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report","volume":"11","author":"Portoles Hernandez","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0067","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0068","article-title":"Progressive and reversible conduction disease with checkpoint inhibitors","volume":"33","author":"Reddy","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0069","article-title":"Autoimmune myocarditis with av block: too much of a good thing?","author":"Robert","year":"2018","journal-title":"Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2017.04.011","article-title":"Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy","volume":"115","author":"Saba","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0071","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.3747\/co.26.4381","article-title":"Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab","volume":"26","author":"Saibil","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0072","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa214","article-title":"A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)","volume":"4","author":"Salido Iniesta","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0074","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/tlcr-20-1095","article-title":"Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report","volume":"10","author":"Schiopu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0075","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1536\/ihj.21-653","article-title":"Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis","volume":"63","author":"Shindo","year":"2022","journal-title":"Int Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0076","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0077","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1002\/ehf2.13545","article-title":"Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery","volume":"8","author":"Stein-Merlob","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.898756","article-title":"Successful therapy for myocarditis concomitant with complete heart block after pembrolizumab treatment for head and neck squamous cell carcinoma: a case report with literature review","volume":"9","author":"Su","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa051","article-title":"Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: a case report","volume":"4","author":"Szuchan","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0080","first-page":"12","article-title":"Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer","author":"Tan","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0081","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235265","article-title":"Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy","volume":"13","author":"Tan","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0082","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2169\/internalmedicine.5412-20","article-title":"Asymptomatic immune checkpoint inhibitor-associated myocarditis","volume":"60","author":"Tanabe","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0083","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo","year":"2020","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0084","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2169\/internalmedicine.5317-20","article-title":"The cytokine expression in patients with cardiac complication after immune checkpoint inhibitor therapy","volume":"60","author":"Tsuruda","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0085","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CAD.0000000000000903","article-title":"Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature","volume":"31","author":"Veccia","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0086","first-page":"933","article-title":"Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report","volume":"391","author":"Wakefield","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0087","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jcpt.13707","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"47","author":"Wang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0088","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/cco.2020.03.08","article-title":"A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China","volume":"9","author":"Wang","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0089","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21037\/atm.2019.04.73","article-title":"Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/CJI.0000000000000390","article-title":"Management and outcomes of hematological immune-related adverse events: systematic review and meta-analysis","volume":"45","author":"Wilson","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0091","article-title":"Case report: fatal multiorgan failure and heterochronous pneumonitis following pembrolizumab treatment in a patient with large-cell neuroendocrine carcinoma of lung","volume":"11","author":"Xie","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0092","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jamainternmed.2022.1226","article-title":"Ominous electrocardiographic abnormalities in a patient with hepatocellular carcinoma","volume":"182","author":"Xu","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0093","first-page":"812.e811","article-title":"Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.797009","article-title":"Sintilimab-induced myocarditis overlapping myositis in a patient with metastatic thymoma: a case report","volume":"8","author":"Yang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma exchange for immune checkpoint inhibitor-induced myocarditis","volume":"3","author":"Yogasundaram","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0096","article-title":"Camrelizumab-related lethal arrhythmias and myasthenic crisis in a patient with metastatic thymoma","volume":"2022","author":"Zhang","year":"2022","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0097","article-title":"Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis","author":"Zhang","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0098","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11936-019-0731-6","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors","volume":"21","author":"Zhang","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0099","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/eurheartj\/ehab158","article-title":"Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis","volume":"42","author":"Zhang","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.asjsur.2021.08.067","article-title":"A case of carrelizumab-associated immune myocarditis","volume":"45","author":"Zhao","year":"2022","journal-title":"Asian J Surg"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0101","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/j.clon.2022.03.006","article-title":"Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses","volume":"34","author":"Zhou","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0102","first-page":"5","article-title":"Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis","volume":"8","author":"Zhou","year":"2022","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cpcardiol.2022.101478_bib0103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002007","article-title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","volume":"9","author":"Zlotoff","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:18Z","timestamp":1758938358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622003759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0146280622003759"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101478","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrocardiographic Features of Immune Checkpoint Inhibitor-Associated Myocarditis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101478"}}